Juvenile myelomonocytic leukemia

Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML

Retrieved on: 
Thursday, November 9, 2023
EHA, CD38, Associate, UCSF Benioff Children's Hospital, European Hematology Association, Juvenile myelomonocytic leukemia, Transplant, Disease, Database, UCSF, Patient, ASCO, Hematopoietic stem cell transplantation, APL, AZA, Blood, Cytarabine, FLA, Cancer, Tretinoin, Acute promyelocytic leukemia, Trial of the century, Malignancy, Society, Physician, Cell, Bone marrow, Drug combination, Pharmaceutical industry, JMML

FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced the publication of data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more effective pre-hematopoietic stem cell transplantation (pre-HSCT) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) in the November 9th Issue of the American Society of Clinical Oncology (ASCO) Journal JCO Precision Oncology. Part of this data was recently presented at the European Hematology Association (EHA) Hybrid Congress held in Frankfurt, Germany on June 8 – 15, 2023. Details of that presentation can be found on the Company’s website at https://notablelabs.com/.

Key Points: 
  • JMML is a rare, aggressive pediatric malignancy for which curative treatment is restricted to hematopoietic stem cell transplantation.
  • Pre-HSCT therapies, i.e., therapies prior to transplantation, include moderately intensive chemotherapy (particularly fludarabine and cytarabine in combination (FLA)) and azacytidine (AZA) monotherapy.
  • Applying its proprietary PPMP technology to blood or bone marrow samples from JMML patients, Notable screened 130 drug combinations and discovered that 27 of these combinations (26 dual-, 1 triple-combination) were more effective ex vivo than the components of these combinations tested individually.
  • “This publication marks the culmination of a multi-year collaboration between UCSF and Notable Labs,” remarked Dr. Stieglitz.

Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress

Retrieved on: 
Friday, June 9, 2023
San Francisco, Tretinoin, University, European Hematology Association, CALC, University of California, San Francisco, Cancer, Juvenile myelomonocytic leukemia, Patient, Drug combination, Cytarabine, EHA, Calcitriol, Poster, Hospital, FLU, Pharmaceutical industry, JMML

FOSTER CITY, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today presented data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more active investigational pre-hematopoietic stem cell therapy (pre-HCST) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) at the European Hematology Association (EHA) Hybrid Congress being held in Frankfurt, Germany on June 8 – 15, 2023.

Key Points: 
  • Of 130 drug combinations, 27 were shown to be more active in killing leukemic cells ex vivo than compounds represented in these combinations on their own.
  • These results highlight PPMP as a potential tool for identifying superior drug combinations for patients with high medical needs, including with JMML.
  • Abstract title: Tretinoin and calcitriol enhance treatment regimens for juvenile myelomonocytic leukemia in ex vivo drug sensitivity assays.
  • Additional meeting information can be found on the 2023 EHA Congress website, https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ .

TeamConnor Childhood Cancer Foundation Announces Grant Recipients in Pediatric Cancer Research for 2023

Retrieved on: 
Thursday, February 9, 2023
DREAM, Juvenile myelomonocytic leukemia, Medicine, Glioma, Speedway Children's Charities, Hospital, St. Baldrick's Foundation, Transplant, Cancer, Lymphoma, Einstein Medical Center Philadelphia, Boston Children's Hospital, Bone marrow, Connor, Texas Motor Speedway, Research, Cincinnati Children's Hospital Medical Center, Neoplasm, Child, Moon, Stand Up to Cancer, Immune system, Dana–Farber Cancer Institute, Gene, Disease, Neuroblastoma, In Honor: A Compilation to Beat Cancer, Partnership, Genomics, Dana, Malignant peripheral nerve sheath tumor, Vaccine, Pharmaceutical industry, Dentistry

DALLAS, Feb. 9, 2023 /PRNewswire/ -- The TeamConnor Childhood Cancer Foundation is proud to continue its work towards eradicating pediatric cancer by awarding $500,000 to multiple research grantees at five national institutions to fund their childhood cancer research work in 2023. As non-profit fundraising opportunities continue to be a challenge, the organization is thankful for the loyal donors, generous foundation grants, and community partners who share in the fight to cure pediatric cancers.

Key Points: 
  • DALLAS, Feb. 9, 2023 /PRNewswire/ -- The TeamConnor Childhood Cancer Foundation is proud to continue its work towards eradicating pediatric cancer by awarding $500,000 to multiple research grantees at five national institutions to fund their childhood cancer research work in 2023.
  • The DREAM team was established as the pediatric cancer research group for Stand Up To Cancer.
  • For more information on how to join the fight against childhood cancer, please visit teamconnor.org or follow TeamConnor Childhood Cancer Foundation on Instagram, Twitter, LinkedIn, YouTube and Facebook.
  • For more information on how to join the fight against childhood cancer, please visit teamconnor.org or follow TeamConnor Childhood Cancer Foundation on Facebook, Instagram, Twitter, LinkedIn, YouTube.